Skip to main content

Table 3 Adverse events recorded during treatment

From: Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

Adverse Events Placebo N = 21 AP N = 23
Serious
Infection
  Herpes simplex virus-1 encephalitis 0 1
  Urinary/pulmonary sepsis, death 1 0
  Pneumonia 1 0
  Influenza 1 0
  Pyelonephritis 0 1
  PML 0 0
Cardiovascular
  Acute coronary syndrome 2 1
  Syncope 2 0
  Pacemaker installation 2 0
Cancer 0 0
Mild – Moderate
Infections
  Upper respiratory tract infection 5 8
  Lower urinary tract infection 1 3
  Gastrointestinal infection 2 2
Other
  Pruriginous rash 0 12
  Dysgeusia 0 3
  Falls 2 4
  Mood/sleep disturbances 1 3
  Gastroesophageal reflux 1 1
  Lumbar pain 1 1
  Joint pain 2 1
  Bursitis 0 1
  Cataract surgery 0 1
  Gastric ulcer 1 0
  Vertigo 1 0
  Constipation 1 0
  1. Comorbidities were balanced between groups (data not shown)